Biodesix, Inc. (BDSX) Q3 2024 Earnings Call Transcript Summary
Biodesix, Inc. (BDSX) Q3 2024 Earnings Call Transcript Summary
Operating expenses increased by 29% year-over-year, primarily due to investments in sales and marketing to boost lung diagnostic testing growth.The following is a summary of the Biodesix, Inc. (BDSX) Q3 2024 Earnings Call Transcript:
以下是biodesix公司（BDSX）2024年第三季度業績會交流摘要：
Financial Performance:
金融業績：
Biodesix reported Q3 revenue of $18.2 million, a 35% year-over-year increase, with lung diagnostic testing generating $17.2 million from 13,900 tests.
Gross margins were reported at 77%, indicating consistent high performance.
Operating expenses increased by 29% year-over-year, primarily due to investments in sales and marketing to boost lung diagnostic testing growth.
The net loss for the quarter improved by 6%, amounting to $10.3 million.
The company remains on track to meet its full-year 2024 revenue guidance of $70 million to $72 million and expects adjusted EBITDA profitability in the second half of 2025.
biodesix報告第三季度營業收入爲1820萬美元，同比增長35%，其中來自13900項測試的肺部診斷測試帶來了1720萬美元的收入。
毛利率報告爲77%，表明持續高性能。
營業費用同比增長29%，主要是由於投資於銷售和營銷以推動肺部診斷測試增長。
本季度淨損失改善了6%，達到1030萬美元。
公司仍然按計劃實現2024年全年營收指引爲7000萬至7200萬美元，並預計在2025年下半年實現調整後的EBITDA盈利能力。
Business Progress:
業務進展：
The company added new coverage policies for Nodify X2 lung diagnostic tests, enhancing payer coverage.
Biodesix presented new data at the CHEST annual meeting, supporting the adoption of Nodify lung tests.
There was a focus on continuous investment in clinical excellence and new studies like CLARIFY to boost test adoption.
The biopharma services saw a contract growth, with $11.1 million in contracted but unrecognized revenue, promising revenue flows in the upcoming periods.
該公司爲Nodify X2肺部診斷測試增加了新的保險政策，增強了支付者的覆蓋範圍。
biodesix在CHESt年會上發佈了新數據，支持Nodify肺部測試的採用。
着重於持續投資於臨床卓越性和諸如CLARIFY之類的新研究，以促進測試的採用。
生物製藥服務業務簽約增長，合同但未確認的營業收入達到1110萬美元，預示着未來時期的營業收入將有所增加。
Opportunities:
機會：
The company is poised for future growth with an increasing number of coverage policies and clinical data supporting the lung diagnostic tests.
Ongoing and upcoming clinical studies (e.g., CLARIFY) and conferences (e.g., CHEST) present opportunities to bolster credibility and adoption of Biodesix's tests.
該公司憑藉不斷增加的覆蓋政策數量和臨床數據的支持，爲未來增長做好準備。
正在進行和即將進行的臨床研究（例如CLARIFY）和會議（例如CHEST）爲增強Biodesix測試的可信度和採用提供了機會。
Risks:
風險：
Natural disasters like hurricanes impacted sales in the Southeast, demonstrating environmental risks that could affect operations and sales.
Delays in biopharma project completions underscore operational risks linked to timing and execution that could influence financial performance.
類似颶風這樣的自然災害影響了東南部地區的銷售，展示了可能影響業務和銷售的環保母基風險。
生物製藥項目完成延誤凸顯了與時間和執行相關的操作風險，可能影響財務績效。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
